0001213900-22-057608.txt : 20220921 0001213900-22-057608.hdr.sgml : 20220921 20220921120934 ACCESSION NUMBER: 0001213900-22-057608 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210625 FILED AS OF DATE: 20220921 DATE AS OF CHANGE: 20220921 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GRUENER GARRETT CENTRAL INDEX KEY: 0001106287 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-54586 FILM NUMBER: 221255603 MAIL ADDRESS: STREET 1: ONE EMBARCADERO CENTER, SUITE 3700 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NANOMIX Corp CENTRAL INDEX KEY: 0001473579 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 270801073 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 354 MERRIMACK STREET STREET 2: #4 CITY: LAWRENCE STATE: MA ZIP: 01843 BUSINESS PHONE: (603) 935-9799 MAIL ADDRESS: STREET 1: 354 MERRIMACK STREET STREET 2: #4 CITY: LAWRENCE STATE: MA ZIP: 01843 FORMER COMPANY: FORMER CONFORMED NAME: Boston Therapeutics, Inc. DATE OF NAME CHANGE: 20101123 FORMER COMPANY: FORMER CONFORMED NAME: AVANYX Therapeutics, Inc. DATE OF NAME CHANGE: 20091001 4 1 ownership.xml X0306 4 2021-06-25 0 0001473579 NANOMIX Corp NNMX 0001106287 GRUENER GARRETT C/O NANOMIX CORP., 2121 WILLIAMS STREET SAN LEANDRO CA 94577 1 0 1 0 Common Stock 2022-03-02 4 C 0 25160338 A 25160338 D Common Stock 2022-08-18 4 P 0 32 0.57 A 25160370 D Common Stock 2022-08-19 4 P 0 2968 0.40 A 25163306 D Common Stock 2022-08-22 4 P 0 1500 0.36 A 25174838 D Common Stock 2022-08-22 4 P 0 11500 0.40 A 25176338 D Senior Secured Convertible Promissory Note 0.0119 2021-06-25 4 J 0 1603778 1603778 A 2021-06-25 2023-06-25 Common Stock 134771261 1603778 D Common Stock Purchase Warrants 0.0119 2021-06-25 4 J 0 134771261 A 2021-06-25 2026-06-25 Common Stock 134771261 134771261 D Senior Secured Convertible Promissory Note 0.0119 2022-02-28 4 P 0 444444 444444 A 2022-02-28 2024-02-28 Common Stock 37348235 2048222 D Common Stock Purchase Warrants 0.0119 2022-02-28 4 P 0 37348235 A 2022-02-28 2027-02-28 Common Stock 37348235 172119496 D On June 25, 2021, Reporting Person exchanged a promissory note in the principal amount of $1,603,778 for (i) a senior secured convertible note for an aggregate principal amount of $1,603,778 (the "June 2021 Note") and (ii) a warrant to purchase 134,771,261 shares of the Issuer's common stock (the "June 2021 Warrant"). The June 2021 Note matures on June 25, 2023. The June 2021 Note is convertible at any time into shares of the Issuer's common stock equal to $0.0119 (the "Conversion Price"). The June 2021 Warrant is exercisable at any time into shares of common stock equal to $0.0119 (the "Exercise Price"). On March 2, 2022, the Conversion Price and Exercise Price were adjusted to $2.0587 upon consummation of the Issuer's previously announced reverse split. The Conversion Price and Exercise Price were again amended to $1.1717 in March 2022. At any time during any Event of Default, the Conversion Price in effect may be equal to the Alternative Conversion Price (as defined in the Note). On February 28, 2022, Reporting Person was issued (i) a senior secured convertible note of the Issuer for an aggregate principal amount of $444,444 (the "February 2022 Note") and (ii) a warrant to purchase 37,348,235 shares of the Issuer's common stock (the "February 2022 Warrant") for an aggregate purchase price of $400,000. The February 2022 Note matures on February 28, 2024. The February 2022 Note is convertible at any time into shares of the Issuer's common stock at the Conversion Price. The June 2021 Warrant is exercisable at any time into shares of the Issuer's common stock at the Exercise Price. On March 2, 2022, the Conversion Price and Exercise Price were adjusted to $2.0587 upon consummation of the Issuer's previously announced reverse split. The Conversion Price and Exercise Price were again amended to $1.1717 in March 2022. At any time during the continuance of any Event of Default, the Conversion Price in effect may be equal to the Alternative Conversion Price. On March 2, 2022, the Reporting Person's Series C Preferred Stock automatically converted into an aggregate of 25,160,338 shares of the Issuer's common stock upon consummation of the Issuer's previously announced reverse stock split. /s/ Garrett Gruener 2022-09-21